Cognivia

The placebo response has biological roots in patients with Parkinson’s disease. This prevalence jeopardizes the ability to clearly demonstrate a study drug’s efficacy – keeping much-needed relief from patients. In this guide, we discuss: 👉 How the placebo problem uniquely plays out in Parkinson's patients 👉 Historical approaches to managing the placebo response in PD 👉 A new strategy to work towards successfully delivering a cure Download the guide to dig in: https://lnkd.in/e68iS-pY

Technology is simply a tool. How we use the technology is where we can make a real difference." 👉Read more from Cognivia Chief Scientific Officer Alvaro Pereira, PhD's insightful philosophy on innovation at Cognivia. https://lnkd.in/eaarFHfX This article is the second in a series about Cognivia's vision as we celebrate 10 years as a company, dedicated to cracking the code on the complex relationship between patient traits and behavior. Read the other parts, here ⬇️ Our vision: https://lnkd.in/eauJZvVY Our innovative platform: https://lnkd.in/eyAsKT5u

As we look ahead to 2025, it's time to reflect and prepare for the challenges ahead. Experts predict significant advancements that will reshape healthcare delivery, patient experience, and medical innovation. Here are some key insights and predictions from industry leaders, including Cognivia's CEO Dominique Demolle Thanks to TechRound ! https://lnkd.in/eg7hbfuf

Today's the day! In just a few short hours, we're going live with ICON plc, Biogen, Tufts Center for the Study of Drug Development and Reed Smith LLP at 10am EST (3pm GMT / 4pm CET) to unpack the FDA's Diversity Action Plan Draft Guidance – and share a unique, integrated approach to not only achieving compliance but also promoting equity in healthcare delivery and access. For those that are already registered, we'll see you there! It's not too late to sign up if you haven't yet. We're looking forward to a productive discussion with many different perspectives. Join us: https://lnkd.in/eAmrbDAF

Don't miss your chance to join the conversation about the FDA's Diversity Action Plan Draft Guidance in tomorrow's live webinar! With regulatory, academic, industry and technology leaders, you will have the opportunity to hear different perspectives – and how they all come together to form a unique, integrated approach to achieving compliance. Register for the live, 60-minute webinar to join the conversation and get your questions answered by these experts: 💡 Tinaya Gray, Global Head Diversity in Clinical Trials, ICON plc 💡 Sian Ratcliffe, PhD, SVP, Head of Quantitative Sciences & Development Operations (QSDO), Biogen 💡 Dominique Demolle, PhD, CEO, Cognivia 💡 Ruby Ford, MPH, Research Analyst, Tufts Center for the Study of Drug Development 💡 (Moderator) Sarah Thompson Schick, JD, MS, Counsel, Life Sciences Health Industry Group (LSHI), Reed Smith LLP Register now: https://lnkd.in/eAmrbDAF

This week! 📣 Our live webinar with experts from Biogen, Tufts Center for the Study of Drug Development, ICON plc, Reed Smith LLP, and Cognivia is on Wednesday, December 4. Together, we will be exploring Diversity Action Plan strategies—from improving patient recruitment and retention to reducing data variability. There's still time to register to join the live conversation! Register here: https://lnkd.in/eAmrbDAF

Wondering how to reach your Diversity Action Plan goals in 2025? This webinar is here to help. Join experts from Biogen, Tufts Center for the Study of Drug Development, ICON plc, Reed Smith LLP and Cognivia on December 4 to explore the concept of an “Integrative Approach” that not only aligns with diversity action plans but also the promotion of equity in healthcare delivery and access. In the webinar, you will learn: ✅ The importance of a coherent and comprehensive diversity action plan-integrated approach ✅ Valuable insights from regulatory, industry and academic leaders ✅ How to mitigate the data variability impact on clinical trial data interpretation when implementing a diversity action plan Register today: https://lnkd.in/eAmrbDAF

Wondering how to reach your Diversity Action Plan goals in 2025? This webinar is here to help. Join experts from Biogen, Tufts Center for the Study of Drug Development, ICON plc, Reed Smith LLP and Cognivia on December 4 to explore the concept of an “Integrative Approach” that not only aligns with diversity action plans but also the promotion of equity in healthcare delivery and access. In the webinar, you will learn: ✅ The importance of a coherent and comprehensive diversity action plan-integrated approach ✅ Valuable insights from regulatory, industry and academic leaders ✅ How to mitigate the data variability impact on clinical trial data interpretation when implementing a diversity action plan Register today: https://lnkd.in/eAmrbDAF

Wishing our US-based customers, partners and team a very happy Thanksgiving!

Cognivia Nominated for "Best Venture Capital Deal – Life Sciences 2024"! We’re thrilled to be shortlisted for this distinguished award, sharing the spotlight with AgomabTherapeutics and PanTera as leaders in M&A, corporate finance, and private equity. This recognition celebrates transformative deals within life sciences, and we’re proud to have Cognivia’s €15.5M funding round included in this prestigious category. Our recent funding—led by Vesalius Biocapital IV, SFPIM, and historical shareholders—was evaluated on its value creation, innovative approach, complex financing structure, and strategic vision. Here’s why Cognivia stands out: • A Catalyst for Innovation in Life Sciences-Tech • A Global Vision Driving International Expansion • A Benchmark for Public-Private Partnership We’re excited to continue this journey with our partners and look forward to celebrating together on November 28, 2024. Thank you for your support!